Listen to this article:

Water, ethanol and methanol extracts of Laurus nobilis have been studied mainly in animals and cell lines. The human paper most often cited is Khan et al. 2009: ground leaf, 1–3 g/day for 30 days in forty people with type 2 diabetes, with reported falls in fasting glucose and LDL. That is a small, short trial of powder, not of a hexane fraction. Quercetin is not the “main compound” of every extract. Procyanidins are better documented in laurel wood than as the dominant leaf-extract marker.

The live C.L.A.I.M.S. worker was unreachable when this text was prepared. The snapshot at app.foodlaw.ai/data/claims.json (2 September 2026) contains no Regulation 432/2012 entry for bay leaf. It does contain SANCO on-hold IDs 3412 (antioxidant / oxidative damage), 3413 (wound healing), 3414 (normal blood circulation), 4427 (pathogen microorganisms) and 4547 (digestive support in a multi-herb mix). Conditions of use are empty. Empty CU is not a free wording licence. None of these records authorises a glucose, LDL or hypertension claim. CJEU C-386/23 (30 April 2025) rejects the shortcut “on hold means you may advertise”.

Three levels of inference: a compound is present; an isolated compound has a mechanism; only an authorised wording, with the right dose and product, may appear in commercial communication.

Culinary leaf and tea are not the same exposure as a concentrated extract. A selective polyphenol process or hexane use may trigger a novel-food assessment under Regulation 2015/2283. Do not change medical treatment on the basis of this article.

Not medical or legal advice. Check EU Register, then SANCO on app.foodlaw.ai, then national enforcement. Context: foodlaw.ai, supplemental.pl.

Sources

  1. Khan et al., J Clin Biochem Nutr. 2009;44:52–56. PMID 19177188.
  2. C.L.A.I.M.S. snapshot 2.09.2026 — IDs 3412, 3413, 3414, 4427, 4547.
  3. Reg. 1924/2006; Reg. 432/2012; Reg. 2015/2283; Reg. 1169/2011 Art. 7(3).
  4. CJEU C-386/23, Novel Nutriology, 30.04.2025.